期刊文献+

TJU103联合CTLA4-Ig对T细胞表型和分泌细胞因子的影响

Effect of Combined Use of TJU103 and CTLA4-Ig on Phenotypes of T Cells and Secretion of Cytokines
下载PDF
导出
摘要 本研究应用HLA半相合供、受者间单向混合淋巴细胞培养 (MLC )体系 ,体外检测了联合应用TJU10 3和CTLA4 Ig对供者T细胞增殖以及表型和分泌细胞因子的影响。结果显示 ,单独应用TJU10 3和CTLA4 Ig均能够降低T细胞的增殖活性 ,二者联合应用具有明显的协同抑制增殖效应 ,并能够使CD4 + CD6 9+ /CD8+ CD6 9+ 比值降低 ,Th1型细胞因子 (TNF α ,IFN γ )分泌减少 ,Th2型细胞因子 (IL 4 )分泌增加。提示TJU10 3和CTLA4 Ig联合应用能够阻断供者T细胞激活的抗原和共刺激双信号通路 ,抑制T细胞的增殖活性 ,使CD4 + CD6 9+ /CD8+ CD6 9+ 比值降低 ,并能够调节Th细胞分化 ,诱导Th细胞免疫偏离 ,使辅助性T细胞更多地向Th2细胞方向分化 ,可以作为一条预防临床HLA半相合造血干细胞移植重度移植物抗宿主病 (GVHD ) To investigate the effect of combined use of TJU103 and CTLA4-Ig on phenotypes of T cells and secretion of cytokines. The proliferation,phenotypes,and secretions of TNF-α, IFN-γ and IL-4 of the antigen-induced T cells after combined stimulation with TJU103 and CTLA4-Ig were determined by means of MTT assay,FACS analysis and ELISA assay. It was found that the combined use of TJU103 and CTLA4-Ig showed a markedly and synergetically inhibitory effect on the proliferation of T cells,although TJU103 or CTLA4-Ig alone could also depress the proliferation of T cells. In addition,the ratio of CD4 +CD69 +/CD8 +CD69 + decreased,and the secretion of Th1-type cytokines (TNF-α,IFN-γ) decreased with an enhanced production of Th2-type cytokine(IL-4). These data suggest that the combined use of TJU103 and CTLA4-Ig can block the co-stimulatory pathway,regulate the differentiation of Th cells and induce the immune shift of Th cells. This may provide a new approach to prevent the development of GVHD in case of semimatched transplantation.
出处 《现代免疫学》 CAS CSCD 北大核心 2004年第2期113-116,共4页 Current Immunology
基金 全军医学科学技术研究"十五"计划重点课题资助项目( 0 1Z0 2 5 0 ) 广州市科技重点攻关计划资助项目 ( 2 0 0 0 Z 0 2 2 0 1)
  • 相关文献

参考文献9

  • 1[1]Scully R, Qin S, Cobbold S, et al. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells[J]. Eur J Immunol, 1994,24:2383.
  • 2[2]Fishman JA,Rubin RH. Infection in organ-transplant recipients[J]. N Engl J Med, 1998,338: 1741.
  • 3[3]Aversa F, Tabilio A, Velardi A, et al. Treatment of high risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype[J]. N Engl J Med, 1998,339:1186.
  • 4[4]Ferrara JLM,Deeg HJ. Graft-versus-host-disease[J]. N Engl J Med,1991,324:667.
  • 5[5]Li S, Gao JM, Satoh TS, et al. A computer screening approach to immunoglobulin superfamily structures and interactions:discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics [J]. Proc Natl Acad Sci USA, 1997,94:73.
  • 6[6]Edling AE,Choksi S, Huang Z, et al. An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis[J]. J Autoimmun,2002,18:169.
  • 7[7]Krakauer T. Coordinate suppression of superantigen-induced cytokine production and T-cell proliferation by a small nonpeptidic inhibitor of class Ⅱ major histocompatibility complex and CD4 interaction[J]. Antimicrob Agents Chemother,2000,44: 1067.
  • 8[8]Jiang H,Braunstein NS,Yu B, et al. CD8+ T cells control the Th phenotype of MBP-reactive CD4+T cells in EAE mice[J]. Proc Natl Acad Sci USA, 2001,98: 6301.
  • 9[9]Zeis M, Uharek L, Hartung G, et al. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Thl- and Th2-type CD4(+)T cells in mice[J]. Hematol J,2001,2:136.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部